Details of the Drug

General Information of Drug (ID: DM3VFPD)

Drug Name
Troglitazone
Synonyms
Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 441.5
Logarithm of the Partition Coefficient (xlogp) 5.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption
The drug is rapidly absorbed []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 16 - 34 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 22.64747 micromolar/kg/day [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Drug dependence Not Available SLC2A4 OTJZG0LD [5]
Obesity Not Available SIRT1 OTAYZMOY [5]
Chemical Identifiers
Formula
C24H27NO5S
IUPAC Name
5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
Canonical SMILES
CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C
InChI
InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)
InChIKey
GXPHKUHSUJUWKP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5591
ChEBI ID
CHEBI:9753
CAS Number
97322-87-7
DrugBank ID
DB00197
TTD ID
D06XZW
VARIDT ID
DR00549
INTEDE ID
DR1651

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) TTZMAO3 PPARG_HUMAN Agonist [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [7]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Gene/Protein Processing [12]
17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) OTV8IASE DHB13_HUMAN Gene/Protein Processing [12]
17-beta-hydroxysteroid dehydrogenase type 6 (HSD17B6) OTSB55D2 H17B6_HUMAN Gene/Protein Processing [12]
2'-5'-oligoadenylate synthase-like protein (OASL) OTZ05YRP OASL_HUMAN Gene/Protein Processing [12]
2-acylglycerol O-acyltransferase 1 (MOGAT1) OTZP43K4 MOGT1_HUMAN Gene/Protein Processing [13]
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 (HSD3B2) OT02MSKN 3BHS2_HUMAN Gene/Protein Processing [14]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Gene/Protein Processing [15]
4-hydroxy-2-oxoglutarate aldolase, mitochondrial (HOGA1) OT7XETW4 HOGA1_HUMAN Gene/Protein Processing [12]
60 kDa heat shock protein, mitochondrial (HSPD1) OTTO1Y11 CH60_HUMAN Gene/Protein Processing [16]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Gene/Protein Processing [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DTT PPARG 2.41E-01 -0.06 -0.25
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.10E-01 -5.91E-02 -3.60E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.82E-04 -1.35E-01 -5.84E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 2.40E-01 -3.31E-02 -1.97E-01
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 6.83E-06 -1.42E-01 -4.93E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Troglitazone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pioglitazone DMKJ485 Moderate Increased metabolism of Troglitazone caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [18]
Coadministration of a Drug Treating the Disease Different from Troglitazone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [19]
Methylergonovine DMBEX4O Moderate Increased metabolism of Troglitazone caused by Methylergonovine mediated induction of CYP450 enzyme. Abortion [JA00] [19]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Thioguanine. Acute myeloid leukaemia [2A60] [20]
Midostaurin DMI6E0R Moderate Increased metabolism of Troglitazone caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [21]
Gilteritinib DMTI0ZO Moderate Increased metabolism of Troglitazone caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [22]
Oliceridine DM6MDCF Moderate Increased metabolism of Troglitazone caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [23]
Loratadine DMF3AN7 Moderate Increased metabolism of Troglitazone caused by Loratadine mediated induction of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [24]
Donepezil DMIYG7Z Moderate Increased metabolism of Troglitazone caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [24]
Ranolazine DM0C9IL Major Increased metabolism of Troglitazone caused by Ranolazine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [25]
Ivabradine DM0L594 Moderate Increased metabolism of Troglitazone caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [26]
Dronedarone DMA8FS5 Moderate Increased metabolism of Troglitazone caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [27]
Nifedipine DMSVOZT Moderate Increased metabolism of Troglitazone caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [24]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [28]
Buspirone DMBS632 Moderate Increased metabolism of Troglitazone caused by Buspirone mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [29]
Alprazolam DMC7XDN Moderate Increased metabolism of Troglitazone caused by Alprazolam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [24]
Clobazam - Lundbeck DMW1OQ0 Moderate Increased metabolism of Troglitazone caused by Clobazam - Lundbeck mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [24]
Voriconazole DMAOL2S Moderate Increased metabolism of Troglitazone caused by Voriconazole mediated induction of CYP450 enzyme. Aspergillosis [1F20] [30]
Montelukast DMD157S Moderate Increased metabolism of Troglitazone caused by Montelukast mediated induction of CYP450 enzyme. Asthma [CA23] [31]
Zileuton DMVRIC2 Moderate Increased metabolism of Troglitazone caused by Zileuton mediated induction of CYP450 enzyme. Asthma [CA23] [24]
Erythromycin DM4K7GQ Moderate Increased metabolism of Troglitazone caused by Erythromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [24]
Telithromycin DMZ4P3A Moderate Increased metabolism of Troglitazone caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [32]
Cariprazine DMJYDVK Moderate Increased metabolism of Troglitazone caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [26]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Troglitazone and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [33]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Troglitazone caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Lapatinib DM3BH1Y Moderate Increased metabolism of Troglitazone caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
LY2835219 DM93VBZ Moderate Increased metabolism of Troglitazone caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Exemestane DM9HPW3 Moderate Increased metabolism of Troglitazone caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [36]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Troglitazone caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Tucatinib DMBESUA Moderate Increased metabolism of Troglitazone caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Palbociclib DMD7L94 Moderate Increased metabolism of Troglitazone caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
Alpelisib DMEXMYK Moderate Increased metabolism of Troglitazone caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [38]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Troglitazone caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Troglitazone caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Toremifene DMQYUWG Moderate Increased metabolism of Troglitazone caused by Toremifene mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Bosutinib DMTI8YE Moderate Increased metabolism of Troglitazone caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Estradiol DMUNTE3 Moderate Increased metabolism of Troglitazone caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Dofetilide DMPN1TW Minor Increased metabolism of Troglitazone caused by Dofetilide mediated induction of CYP450 enzyme. Cardiac arrhythmia [BC9Z] [43]
Atorvastatin DMF28YC Moderate Increased metabolism of Troglitazone caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [44]
Macitentan DMP79A1 Moderate Increased metabolism of Troglitazone caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [45]
PF-04449913 DMSB068 Moderate Increased metabolism of Troglitazone caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [46]
Irinotecan DMP6SC2 Moderate Increased metabolism of Troglitazone caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [47]
Drospirenone DM1A9W3 Moderate Increased metabolism of Troglitazone caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [48]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Troglitazone caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [48]
Desogestrel DM27U4Y Moderate Increased metabolism of Troglitazone caused by Desogestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [49]
Ulipristal DMBNI20 Moderate Increased metabolism of Troglitazone caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [26]
Mestranol DMG3F94 Moderate Increased metabolism of Troglitazone caused by Mestranol mediated induction of CYP450 enzyme. Contraceptive management [QA21] [49]
Etonogestrel DMKA8J4 Moderate Increased metabolism of Troglitazone caused by Etonogestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [48]
Lidocaine DML4ZOT Minor Increased metabolism of Troglitazone caused by Lidocaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [50]
Alfentanil DMVO0UB Moderate Increased metabolism of Troglitazone caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [51]
Methadone DMTW6IU Moderate Increased metabolism of Troglitazone caused by Methadone mediated induction of CYP450 enzyme. Cough [MD12] [52]
Dextromethorphan DMUDJZM Moderate Increased metabolism of Troglitazone caused by Dextromethorphan mediated induction of CYP450 enzyme. Cough [MD12] [24]
Mifepristone DMGZQEF Moderate Increased metabolism of Troglitazone caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [53]
Osilodrostat DMIJC9X Moderate Increased metabolism of Troglitazone caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [32]
Ivacaftor DMZC1HS Moderate Increased metabolism of Troglitazone caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [54]
MK-8228 DMOB58Q Moderate Decreased metabolism of Troglitazone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [55]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Troglitazone caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [56]
Aprepitant DM053KT Moderate Increased metabolism of Troglitazone caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [57]
Sertraline DM0FB1J Moderate Increased metabolism of Troglitazone caused by Sertraline mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [24]
Imipramine DM2NUH3 Moderate Increased metabolism of Troglitazone caused by Imipramine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [24]
Vilazodone DM4LECQ Moderate Increased metabolism of Troglitazone caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [58]
Nefazodone DM4ZS8M Moderate Increased metabolism of Troglitazone caused by Nefazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [24]
Vortioxetine DM6F1PU Moderate Increased metabolism of Troglitazone caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [59]
Mirtazapine DML53ZJ Moderate Increased metabolism of Troglitazone caused by Mirtazapine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [60]
Venlafaxine DMR6QH0 Moderate Increased metabolism of Troglitazone caused by Venlafaxine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [24]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Troglitazone caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [61]
Diazepam DM08E9O Moderate Increased metabolism of Troglitazone caused by Diazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [24]
Zonisamide DM0DTF7 Moderate Increased metabolism of Troglitazone caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [62]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Troglitazone caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [63]
Cenobamate DM8KLU9 Moderate Increased metabolism of Troglitazone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [64]
Stiripentol DMMSDOY Moderate Increased metabolism of Troglitazone caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Carbamazepine DMZOLBI Moderate Increased metabolism of Troglitazone caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [24]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Cannabidiol. Epileptic encephalopathy [8A62] [26]
Nicardipine DMCDYW7 Moderate Increased metabolism of Troglitazone caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [24]
Praziquantel DMOU1PK Moderate Increased metabolism of Troglitazone caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [65]
Tazemetostat DMWP1BH Moderate Increased metabolism of Troglitazone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [66]
Solifenacin DMG592Q Moderate Increased metabolism of Troglitazone caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [67]
Mirabegron DMS1GYT Minor Increased metabolism of Troglitazone caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [68]
Darifenacin DMWXLYZ Moderate Increased metabolism of Troglitazone caused by Darifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [69]
Ripretinib DM958QB Moderate Increased metabolism of Troglitazone caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [19]
Sunitinib DMCBJSR Moderate Increased metabolism of Troglitazone caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [19]
Avapritinib DMK2GZX Moderate Increased metabolism of Troglitazone caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [26]
Ergotamine DMKR3C5 Moderate Increased metabolism of Troglitazone caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [19]
Rifapentine DMCHV4I Moderate Increased metabolism of Troglitazone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [70]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Brentuximab vedotin. Hodgkin lymphoma [2B30] [71]
Indinavir DM0T3YH Moderate Increased metabolism of Troglitazone caused by Indinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
MK-1439 DM215WE Moderate Increased metabolism of Troglitazone caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Delavirdine DM3NF5G Moderate Increased metabolism of Troglitazone caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [74]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Troglitazone caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Fostemsavir DM50ILT Minor Increased metabolism of Troglitazone caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [32]
Nevirapine DM6HX9B Moderate Increased metabolism of Troglitazone caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [24]
Efavirenz DMC0GSJ Moderate Increased metabolism of Troglitazone caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Dolutegravir DMCZGRE Minor Increased metabolism of Troglitazone caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [76]
Saquinavir DMG814N Moderate Increased metabolism of Troglitazone caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Etravirine DMGV8QU Moderate Increased metabolism of Troglitazone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [77]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Troglitazone caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [19]
Amprenavir DMLMXE0 Moderate Increased metabolism of Troglitazone caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [78]
Darunavir DMN3GCH Moderate Increased metabolism of Troglitazone caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Atazanavir DMSYRBX Moderate Increased metabolism of Troglitazone caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Maraviroc DMTL94F Moderate Increased metabolism of Troglitazone caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [19]
Ritonavir DMU764S Moderate Increased metabolism of Troglitazone caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Raltegravir DMYURI6 Minor Increased metabolism of Troglitazone caused by Raltegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [79]
Simvastatin DM30SGU Moderate Increased metabolism of Troglitazone caused by Simvastatin mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [24]
Lovastatin DM9OZWQ Moderate Increased metabolism of Troglitazone caused by Lovastatin mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [24]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Troglitazone and Mipomersen. Hyper-lipoproteinaemia [5C80] [80]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Troglitazone and Teriflunomide. Hyper-lipoproteinaemia [5C80] [79]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Troglitazone and BMS-201038. Hyper-lipoproteinaemia [5C80] [81]
Losartan DM72JXH Moderate Increased metabolism of Troglitazone caused by Losartan mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [24]
Levamlodipine DM92S6N Moderate Increased metabolism of Troglitazone caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [24]
Verapamil DMA7PEW Moderate Increased metabolism of Troglitazone caused by Verapamil mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [24]
Diltiazem DMAI7ZV Moderate Increased metabolism of Troglitazone caused by Diltiazem mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [82]
Amlodipine DMBDAZV Moderate Increased metabolism of Troglitazone caused by Amlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [24]
Felodipine DMOSW35 Moderate Increased metabolism of Troglitazone caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [24]
Conivaptan DM1V329 Moderate Decreased metabolism of Troglitazone caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [83]
Tolvaptan DMIWFRL Moderate Increased metabolism of Troglitazone caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [26]
Rhucin DM3ADGP Moderate Increased metabolism of Troglitazone caused by Rhucin mediated induction of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [84]
Ramelteon DM7IW9J Moderate Increased metabolism of Troglitazone caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [85]
Eszopiclone DM8RZ9H Moderate Increased metabolism of Troglitazone caused by Eszopiclone mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [86]
Triazolam DMETYK5 Moderate Increased metabolism of Troglitazone caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [24]
Zaleplon DMGFWSM Minor Increased metabolism of Troglitazone caused by Zaleplon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [87]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Troglitazone caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [88]
ITI-007 DMUQ1DO Major Increased metabolism of Troglitazone caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [89]
Zolpidem DMWOSKJ Moderate Increased metabolism of Troglitazone caused by Zolpidem mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [26]
Naloxegol DML0B41 Moderate Increased metabolism of Troglitazone caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [90]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Methotrexate. Leukaemia [2A60-2B33] [26]
Pemigatinib DM819JF Moderate Increased metabolism of Troglitazone caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [91]
Testosterone DM7HUNW Moderate Increased metabolism of Troglitazone caused by Testosterone mediated induction of CYP450 enzyme. Low bone mass disorder [FB83] [24]
Crizotinib DM4F29C Moderate Increased metabolism of Troglitazone caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [92]
Brigatinib DM7W94S Moderate Increased metabolism of Troglitazone caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [19]
Erlotinib DMCMBHA Moderate Increased metabolism of Troglitazone caused by Erlotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [93]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Troglitazone caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [94]
PF-06463922 DMKM7EW Moderate Increased metabolism of Troglitazone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [95]
Osimertinib DMRJLAT Moderate Increased metabolism of Troglitazone caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [96]
Capmatinib DMYCXKL Moderate Increased metabolism of Troglitazone caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [97]
Selpercatinib DMZR15V Moderate Increased metabolism of Troglitazone caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [32]
Artemether DM48QOT Moderate Increased metabolism of Troglitazone caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [19]
Quinine DMSWYF5 Moderate Increased metabolism of Troglitazone caused by Quinine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [98]
Mefloquine DMWT905 Moderate Increased metabolism of Troglitazone caused by Mefloquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [99]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Idelalisib. Mature B-cell leukaemia [2A82] [100]
GDC-0199 DMH0QKA Moderate Increased metabolism of Troglitazone caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [101]
IPI-145 DMWA24P Moderate Increased metabolism of Troglitazone caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [102]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Troglitazone caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [103]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Clofarabine. Mature B-cell lymphoma [2A85] [104]
Ibrutinib DMHZCPO Moderate Increased metabolism of Troglitazone caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [105]
Vincristine DMINOX3 Moderate Increased metabolism of Troglitazone caused by Vincristine mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [24]
Ponatinib DMYGJQO Moderate Increased metabolism of Troglitazone caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [19]
Vemurafenib DM62UG5 Moderate Increased metabolism of Troglitazone caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [106]
Selumetinib DMC7W6R Moderate Increased metabolism of Troglitazone caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [107]
LGX818 DMNQXV8 Moderate Increased metabolism of Troglitazone caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [108]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Troglitazone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [19]
Conjugated estrogens DMLT0E1 Moderate Increased metabolism of Troglitazone caused by Conjugated estrogens mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [37]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Troglitazone caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [49]
Nitisinone DMVS9WQ Moderate Increased metabolism of Troglitazone caused by Nitisinone mediated induction of CYP450 enzyme. Metabolism inborn error [5C50] [24]
Methysergide DM1EF73 Moderate Increased metabolism of Troglitazone caused by Methysergide mediated induction of CYP450 enzyme. Migraine [8A80] [19]
Dihydroergotamine DM5IKUF Moderate Increased metabolism of Troglitazone caused by Dihydroergotamine mediated induction of CYP450 enzyme. Migraine [8A80] [19]
Ubrogepant DM749I3 Moderate Increased metabolism of Troglitazone caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [109]
Exjade DMHPRWG Moderate Decreased metabolism of Troglitazone caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [110]
Flibanserin DM70DTN Moderate Increased metabolism of Troglitazone caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [111]
Midazolam DMXOELT Moderate Increased metabolism of Troglitazone caused by Midazolam mediated induction of CYP450 enzyme. Mood/affect symptom [MB24] [24]
Panobinostat DM58WKG Moderate Increased metabolism of Troglitazone caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [112]
Bexarotene DMOBIKY Minor Increased metabolism of Troglitazone caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [113]
Fedratinib DM4ZBK6 Moderate Increased metabolism of Troglitazone caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [24]
Nilotinib DM7HXWT Moderate Increased metabolism of Troglitazone caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [114]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Troglitazone caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [115]
Imatinib DM7RJXL Moderate Increased metabolism of Troglitazone caused by Imatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [116]
Dasatinib DMJV2EK Moderate Increased metabolism of Troglitazone caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [19]
Modafinil DMYILBE Moderate Increased metabolism of Troglitazone caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [117]
Rolapitant DM8XP26 Moderate Increased metabolism of Troglitazone caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [118]
Granisetron DMIUW25 Moderate Increased metabolism of Troglitazone caused by Granisetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [24]
Entrectinib DMMPTLH Moderate Increased metabolism of Troglitazone caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [26]
S-297995 DM26IH8 Moderate Increased metabolism of Troglitazone caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [24]
Olaparib DM8QB1D Moderate Increased metabolism of Troglitazone caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [19]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Troglitazone caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [119]
Butorphanol DM5KYPJ Moderate Increased metabolism of Troglitazone caused by Butorphanol mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [52]
Codeine DMJX6ZG Moderate Increased metabolism of Troglitazone caused by Codeine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [24]
Buprenorphine DMPRI8G Moderate Increased metabolism of Troglitazone caused by Buprenorphine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [120]
Hydrocodone DMQ2JO5 Moderate Increased metabolism of Troglitazone caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [52]
Oxycodone DMXLKHV Moderate Increased metabolism of Troglitazone caused by Oxycodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [52]
Pimavanserin DMR7IVC Moderate Increased metabolism of Troglitazone caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [121]
Bromocriptine DMVE3TK Moderate Increased metabolism of Troglitazone caused by Bromocriptine mediated induction of CYP450 enzyme. Parkinsonism [8A00] [24]
Abametapir DM2RX0I Moderate Decreased metabolism of Troglitazone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [122]
Macimorelin DMQYJIR Moderate Increased metabolism of Troglitazone caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [123]
Dapsone DM4LT8A Moderate Increased metabolism of Troglitazone caused by Dapsone mediated induction of CYP450 enzyme. Pneumonia [CA40] [24]
Lefamulin DME6G97 Moderate Increased metabolism of Troglitazone caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [124]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Troglitazone caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [24]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Troglitazone caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [125]
Progesterone DMUY35B Moderate Increased metabolism of Troglitazone caused by Progesterone mediated induction of CYP450 enzyme. Preterm labour/delivery [JB00] [37]
Enzalutamide DMGL19D Moderate Increased metabolism of Troglitazone caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [126]
Darolutamide DMV7YFT Moderate Increased metabolism of Troglitazone caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [127]
Silodosin DMJSBT6 Moderate Increased metabolism of Troglitazone caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [19]
Apremilast DMTWS9E Moderate Increased metabolism of Troglitazone caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [128]
Bosentan DMIOGBU Moderate Increased metabolism of Troglitazone caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [129]
Riociguat DMXBLMP Moderate Increased metabolism of Troglitazone caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [130]
Everolimus DM8X2EH Moderate Increased metabolism of Troglitazone caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [19]
Axitinib DMGVH6N Moderate Increased metabolism of Troglitazone caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [131]
Temsirolimus DMS104F Moderate Increased metabolism of Troglitazone caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [19]
Sorafenib DMS8IFC Moderate Increased metabolism of Troglitazone caused by Sorafenib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [132]
Tofacitinib DMBS370 Moderate Increased metabolism of Troglitazone caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [19]
Dexamethasone DMMWZET Moderate Increased metabolism of Troglitazone caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [24]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Troglitazone and Leflunomide. Rheumatoid arthritis [FA20] [79]
Quetiapine DM1N62C Moderate Increased metabolism of Troglitazone caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [19]
Aripiprazole DM3NUMH Moderate Increased metabolism of Troglitazone caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [133]
Chlorpromazine DMBGZI3 Moderate Increased metabolism of Troglitazone caused by Chlorpromazine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [24]
Ziprasidone DMM58JY Minor Increased metabolism of Troglitazone caused by Ziprasidone mediated induction of CYP450 enzyme. Schizophrenia [6A20] [134]
Pimozide DMW83TP Moderate Increased metabolism of Troglitazone caused by Pimozide mediated induction of CYP450 enzyme. Schizophrenia [6A20] [24]
Fentanyl DM8WAHT Moderate Increased metabolism of Troglitazone caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [52]
Avanafil DM75CXN Moderate Increased metabolism of Troglitazone caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [135]
Yohimbine DMJCP1Y Moderate Increased metabolism of Troglitazone caused by Yohimbine mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [136]
LDE225 DMM9F25 Moderate Increased metabolism of Troglitazone caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [137]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Troglitazone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [26]
Gefitinib DM15F0X Moderate Increased metabolism of Troglitazone caused by Gefitinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [93]
Larotrectinib DM26CQR Moderate Increased metabolism of Troglitazone caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [19]
Cyclophosphamide DM4O2Z7 Moderate Increased metabolism of Troglitazone caused by Cyclophosphamide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
Vinblastine DM5TVS3 Moderate Increased metabolism of Troglitazone caused by Vinblastine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
Ifosfamide DMCT3I8 Moderate Increased metabolism of Troglitazone caused by Ifosfamide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
Docetaxel DMDI269 Moderate Increased metabolism of Troglitazone caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [138]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [26]
Armodafinil DMGB035 Moderate Increased metabolism of Troglitazone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [117]
LEE011 DMMX75K Moderate Decreased metabolism of Troglitazone caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [139]
Norethindrone DMTY169 Moderate Increased metabolism of Troglitazone caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
Taxol DMUOT9V Moderate Increased metabolism of Troglitazone caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [140]
Doxorubicin DMVP5YE Moderate Increased metabolism of Troglitazone caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Troglitazone and Naltrexone. Substance abuse [6C40] [141]
Warfarin DMJYCVW Moderate Decreased metabolism of Troglitazone caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [142]
Fostamatinib DM6AUHV Moderate Increased metabolism of Troglitazone caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [32]
Apixaban DM89JLN Moderate Increased metabolism of Troglitazone caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [143]
Brilinta DMBR01X Moderate Increased metabolism of Troglitazone caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [79]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Troglitazone caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [144]
Sirolimus DMGW1ID Moderate Increased metabolism of Troglitazone caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [19]
Tacrolimus DMZ7XNQ Moderate Increased metabolism of Troglitazone caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [19]
Saxagliptin DMGXENV Moderate Increased metabolism of Troglitazone caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [145]
Linagliptin DMWFJTR Moderate Increased metabolism of Troglitazone caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [146]
Elagolix DMB2C0E Moderate Increased metabolism of Troglitazone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [147]
Amiodarone DMUTEX3 Moderate Increased metabolism of Troglitazone caused by Amiodarone mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [24]
⏷ Show the Full List of 233 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2693).
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6 Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
7 Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
8 In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
9 Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1260-6.
10 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
11 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
12 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
13 Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
14 Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
15 PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. FEBS Lett. 2002 Jun 5;520(1-3):177-81.
16 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
17 Troglitazone but not conjugated linoleic acid reduces gene expression and activity of matrix-metalloproteinases-2 and -9 in PMA-differentiated THP-1 macrophages. J Nutr Biochem. 2008 Sep;19(9):594-603. doi: 10.1016/j.jnutbio.2007.08.003. Epub 2007 Dec 21.
18 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
19 Cerner Multum, Inc. "Australian Product Information.".
20 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
21 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
22 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
23 Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9. [PMID: 3378383]
24 Burgess SJ, Singer GG, Brennan DC "Effect of troglitazone on cyclosporine whole blood levels." Transplantation 66 (1998): 272. [PMID: 9701278]
25 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
26 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
28 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
29 Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
30 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
31 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
32 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
33 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
34 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
35 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
36 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
37 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
38 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
39 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
40 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
41 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
42 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43 Product Information. Tikosyn (dofetilide) Pfizer US Pharmaceuticals, Atlanta, GA.
44 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
45 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
46 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
47 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
48 FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 31 (2005): 139-51. [PMID: 15921558]
49 Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ "Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent." J Clin Pharmacol 39 (1999): 410-7. [PMID: 10197300]
50 Heinonen J, Takki S, Jarho L "Plasma lidocaine levels in patients treated with potential inducers of microsomal enzymes." Acta Anaesthesiol Scand 14 (1970): 89-95. [PMID: 5428253]
51 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
52 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
53 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
54 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
55 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
56 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
57 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
58 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
59 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
60 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
61 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
62 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
63 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
64 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
65 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
66 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
67 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
68 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
69 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
70 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
71 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
72 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
73 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
74 Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
75 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
76 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
77 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
78 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
79 Canadian Pharmacists Association.
80 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
81 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
82 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
83 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
84 Hyland R, Roe GH, Jones BC, Smith DA "Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil." Br J Clin Pharmaacol 51 (2001): 239-48. [PMID: 11298070]
85 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
86 Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
87 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
88 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
89 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
90 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
91 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
92 Cerner Multum, Inc. "Canadian Product Information.".
93 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
94 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
95 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
96 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
97 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
98 Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
99 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
100 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
101 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
102 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
103 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
104 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
105 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
106 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
107 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
108 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
109 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
110 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
111 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
112 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
113 Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.
114 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
115 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
116 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
117 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
118 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
119 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
120 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
121 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
122 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
123 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
124 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
125 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
126 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
127 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
128 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
129 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
130 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
131 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
132 Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
133 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
134 Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A "The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers." Br J Clin Pharmacol 49(suppl 1) (2000): s65-70. [PMID: 10771457]
135 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
136 Fraser CG, Fierro L "Comment: troglitazone." Ann Pharmacother 32 (1998): 1111-2. [PMID: 9793612]
137 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
138 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
139 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
140 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
141 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
142 Plowman BK, Morreale AP "Possible troglitazone-warfarin interaction." Am J Health Syst Pharm 55 (1998): 1071. [PMID: 9606460]
143 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
144 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
145 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
146 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
147 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.